These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

833 related items for PubMed ID: 17553535

  • 1. Chronic SKF83959 induced less severe dyskinesia and attenuated L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.
    Zhang H, Ma L, Wang F, Chen J, Zhen X.
    Neuropharmacology; 2007 Jul; 53(1):125-33. PubMed ID: 17553535
    [Abstract] [Full Text] [Related]

  • 2. L-stepholidine reduced L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.
    Mo J, Zhang H, Yu LP, Sun PH, Jin GZ, Zhen X.
    Neurobiol Aging; 2010 Jun; 31(6):926-36. PubMed ID: 18707801
    [Abstract] [Full Text] [Related]

  • 3. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
    Muñoz A, Li Q, Gardoni F, Marcello E, Qin C, Carlsson T, Kirik D, Di Luca M, Björklund A, Bezard E, Carta M.
    Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
    [Abstract] [Full Text] [Related]

  • 4. The role of the phosphatidyinositol-linked D1 dopamine receptor in the pharmacology of SKF83959.
    Zhen X, Goswami S, Friedman E.
    Pharmacol Biochem Behav; 2005 Apr; 80(4):597-601. PubMed ID: 15820529
    [Abstract] [Full Text] [Related]

  • 5. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Henry B, Crossman AR, Brotchie JM.
    Exp Neurol; 1998 Jun; 151(2):334-42. PubMed ID: 9628768
    [Abstract] [Full Text] [Related]

  • 6. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.
    Henry B, Crossman AR, Brotchie JM.
    Exp Neurol; 1999 Feb; 155(2):204-20. PubMed ID: 10072296
    [Abstract] [Full Text] [Related]

  • 7. Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson's disease.
    Kobylecki C, Cenci MA, Crossman AR, Ravenscroft P.
    J Neurochem; 2010 Jul; 114(2):499-511. PubMed ID: 20456008
    [Abstract] [Full Text] [Related]

  • 8. Neuroprotective effect of L-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinson's disease.
    Agnati LF, Leo G, Vergoni AV, Martínez E, Hockemeyer J, Lluis C, Franco R, Fuxe K, Ferré S.
    Brain Res Bull; 2004 Aug 30; 64(2):155-64. PubMed ID: 15342103
    [Abstract] [Full Text] [Related]

  • 9. Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease.
    Visanji NP, Fox SH, Johnston T, Reyes G, Millan MJ, Brotchie JM.
    Neurobiol Dis; 2009 Aug 30; 35(2):184-92. PubMed ID: 19118628
    [Abstract] [Full Text] [Related]

  • 10. A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease.
    Johnston TH, Lee J, Gomez-Ramirez J, Fox SH, Brotchie JM.
    Exp Neurol; 2005 Feb 30; 191(2):243-50. PubMed ID: 15649479
    [Abstract] [Full Text] [Related]

  • 11. The partial 5-HT(1A) agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy.
    Eskow KL, Gupta V, Alam S, Park JY, Bishop C.
    Pharmacol Biochem Behav; 2007 Feb 30; 87(3):306-14. PubMed ID: 17553556
    [Abstract] [Full Text] [Related]

  • 12. BN82451 attenuates L-dopa-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.
    Spinnewyn B, Mautino G, Marin JG, Rocher MN, Grandoulier AS, Ferrandis E, Auguet M, Chabrier PE.
    Neuropharmacology; 2011 Mar 30; 60(4):692-700. PubMed ID: 21129389
    [Abstract] [Full Text] [Related]

  • 13. Transcription factors involved in the pathogenesis of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
    Cenci MA.
    Amino Acids; 2002 Mar 30; 23(1-3):105-9. PubMed ID: 12373525
    [Abstract] [Full Text] [Related]

  • 14. The selective D(3) receptor antagonist, S33084, improves parkinsonian-like motor dysfunction but does not affect L-DOPA-induced dyskinesia in 6-hydroxydopamine hemi-lesioned rats.
    Mela F, Millan MJ, Brocco M, Morari M.
    Neuropharmacology; 2010 Feb 30; 58(2):528-36. PubMed ID: 19733554
    [Abstract] [Full Text] [Related]

  • 15. Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson's disease and L-DOPA-induced dyskinesia.
    Kobylecki C, Crossman AR, Ravenscroft P.
    Exp Neurol; 2013 Sep 30; 247():476-84. PubMed ID: 23360800
    [Abstract] [Full Text] [Related]

  • 16. Serotonergic and dopaminergic mechanisms in graft-induced dyskinesia in a rat model of Parkinson's disease.
    Shin E, Garcia J, Winkler C, Björklund A, Carta M.
    Neurobiol Dis; 2012 Sep 30; 47(3):393-406. PubMed ID: 22579773
    [Abstract] [Full Text] [Related]

  • 17. ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice.
    Pavón N, Martín AB, Mendialdua A, Moratalla R.
    Biol Psychiatry; 2006 Jan 01; 59(1):64-74. PubMed ID: 16139809
    [Abstract] [Full Text] [Related]

  • 18. Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.
    Yang X, Zhao H, Shi H, Wang X, Zhang S, Zhang Z, Zu J, Zhang W, Shen X, Cui G, Hua F.
    Exp Neurol; 2015 Sep 01; 271():168-74. PubMed ID: 26001615
    [Abstract] [Full Text] [Related]

  • 19. Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease.
    Mela F, Marti M, Dekundy A, Danysz W, Morari M, Cenci MA.
    J Neurochem; 2007 Apr 01; 101(2):483-97. PubMed ID: 17359492
    [Abstract] [Full Text] [Related]

  • 20. The effect of chronic administration of sarizotan, 5-HT1A agonist/D3/D4 ligand, on haloperidol-induced repetitive jaw movements in rat model of tardive dyskinesia.
    Rosengarten H, Bartoszyk GD, Quartermain D, Lin Y.
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Mar 01; 30(2):273-9. PubMed ID: 16229932
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.